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Abstract
Background: Osteosarcoma is the most common bone tumor and is associated with a poor prognosis.
Conventional therapies, surgery and chemotherapy, are still the standard but soon reach their limits. New
therapeutic approaches are therefore needed. Conventional aqueous mistletoe extracts from the European
mistletoe (Viscum album L.) are used in complementary cancer treatment. These commercial extracts are
water-based and do not include water-insoluble compounds such as triterpenic acids. However, both hydrophilic
and hydrophobic triterpenic acids possess anti-cancer properties. In this study, a whole mistletoe extract viscumTT
re-created by combining an aqueous extract (viscum) and a triterpene extract (TT) was tested for its anti-cancer
potential in osteosarcoma.
Methods: Two osteosarcoma cell lines were treated with three different mistletoe extracts viscum, TT and
viscumTT to compare their apoptotic potential. For this purpose, annexin/PI staining and caspase-3, −8 and −9 activity
were investigated by flow cytometry. To determine the mechanism of action, alterations in expression of inhibitors of
apoptosis (IAPs) were detected by western blot. Apoptosis induction by co-treatment of viscum, TT and viscumTT with
doxorubicin, etoposide and ifosfamide was examined by flow cytometry.
Results: In vitro as well as ex vivo, the whole mistletoe extract viscumTT led to strong inhibition of proliferation and
synergistic apoptosis induction in osteosarcoma cells. In the investigations of mechanism of action, inhibitors of
apoptosis such as XIAP, BIRC5 and CLSPN showed a clear down-regulation after viscumTT treatment. In addition,
co-treatment with doxorubicin, etoposide and ifosfamide further enhanced apoptosis induction, also synergistically.
Conclusion: ViscumTT treatment results in synergistic apoptosis induction in osteosarcoma cells in vitro and ex vivo.
Additionally, conventional standard chemotherapeutic drugs such as doxorubicin, etoposide and ifosfamide were able
to dramatically enhance apoptosis induction. These results promise a high potential of viscumTT as an additional
adjuvant therapy approach for osteosarcoma.
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Background
Osteosarcoma (OS) is the most common bone tumor with
a worldwide incidence of four to five cases annually per
million [1]. Nowadays, conventional treatment of osteo-
sarcomas is still surgery with subsequent combined
chemotherapy (multidisciplinary therapy). High-grade
osteosarcoma tends to develop pulmonary metastasis, and
such patients and recurrent patients have a distinctly
worse prognosis. Additionally, standard therapies carry
the problem of chemotherapy resistance. In the future
new adjuvant therapy approaches will be necessary.
Viscum album L. extracts (VAEs) are widespread in
complementary cancer medicine in Europe and used in
several cancer types [2, 3]. Viscum album L. includes a
large number of chemically different substances: lectins
[4], triterpenic acids [5], viscotoxins [6], phenolic acids
[7], flavonoids [8], oligo- and polysaccharides [9, 10] and
some others. The commercial aqueous VAEs contain
mainly mistletoe lectins (MLs) I-III [4] and viscotoxins
(VT) [6, 11], and for MLs various biologically activities
are known. Cytotoxic and apoptotic potential of MLs
have been shown in human lymphocytes [12, 13] and in
head and neck squamous cell carcinoma cell lines [14].
VAE treatment led to a significant prolongation of the
median overall survival in patients with advanced pan-
creatic cancer [3]. The basic mechanism of action of Vis-
cum album L. is not fully understood. Both the
European mistletoe as well as the Korean mistletoe me-
diated apoptosis induction by activation of the PI3K/
AKT pathway [15], JNK/p38/MAPK [16] signalling and
caspase cascades [13, 17]. Our group demonstrated
apoptosis induction in vitro and in vivo in acute lympho-
blastic leukaemia (ALL) [18], in acute myeloid leukaemia
(AML) [19] as well as recently in Ewing’s sarcoma
(Twardziok et al. accepted). Additionally, down-
regulation of inhibitor of apoptosis proteins (IAPs), such
as BIRC5 and XIAP was observed in Ewing’s sarcoma
cell lines (Twardziok et al. accepted). Activation of the
mitochondrial apoptotic pathway was demonstrated in-
ter alia in AML [19], ALL [18] and other cancer cell
lines [20].
In addition to MLs and viscotoxins, Viscum album L.
contains hydrophobic compounds, pentacyclic triterpe-
nic acids, such as oleanolic (OA) and betulinic (BA) acid.
Because of their low water solubility they are not in-
cluded in VAEs. OA and BA possess anti-cancer effects
in different tumor entities. OA arrested the cell cycle
and led to apoptosis induction in pancreatic [21] and
osteosarcoma cells [22] while BA induced mitochondria
mediated apoptosis in neuroectodermal tumors [23].
To potentiate all anti-cancer effects of each mistletoe
compound, a whole mistletoe extract viscumTT was cre-
ated by combining mistletoe derived triterpenic acids
(TT), which were solubilized by β-cyclodextrins (CD) [24],
and a water-based extract (viscum). In recent investiga-
tions we and others were able to determine a synergistic
apoptosis induction for viscumTT in comparison to the
single extracts viscum or TT in leukemia (ALL, AML)
[18, 19] and Ewing’s sarcoma (Twardziok et al. accepted)
and in murine melanoma in vitro and in vivo [25].
It is already known that adjuvant therapy with VAEs
reduces side effects during chemotherapy [26]. Addition-
ally, the impact of various conventional chemotherapeu-
tic drugs can be increased by VAEs as was recently
shown in leukaemia cells [27], breast carcinoma and
pancreatic cancer cells [28]. The influence of viscumTT
co-treatment of osteosarcoma with standard chemother-
apy such as doxorubicin (Doxo), etoposide (VP16) and
ifosfamide (4OOH) was investigated in this study.
Methods
Viscum album L. extracts
Viscum album L. extracts were kindly provided by Bir-
ken AG (Niefern-Oeschelbronn, Germany). Preparation
of Viscum album L. extracts from apple tree (malus) was
performed as described previously [18, 29]. Intact mistle-
toe lectin I (A + B chain) in viscum extract was analyzed
by ELISA [19]. Both the aqueous mistletoe extract vis-
cum and the triterpene extract TT were solubilized in
phosphate buffered saline PBS resulting in a final con-
centration of 2 μg/mL intact ML-I, < 1 μg/mL viscotox-
ins (viscum), 4000 μg/mL OA and 0.35 μg/mL BA (TT)
(Table. 1). As whole mistletoe extract (viscumTT) a
combination of the two single extracts (TT and viscum)
was added to the cells.
Material and reagents
RPMI 1640, McCoy’s 5A, penicillin, streptomycin, trypsin
(0.05%) and PBS were purchased from Gibco, Lifetechnolo-
gies (Darmstadt, Germany). Fetal Calf Serum (FCS) was
obtained from Biochrom (Berlin, Germany). Protein inhibi-
tors, molecular mass standards for SDS-PAGE, sodium
dodecyl sulphate (SDS), dimethyl sulfoxide (DMSO), VP16,
5, 5, 6, 6-tetrachloro-1, 1, 3, 3-tetraethylbenzimidazol-











TT 230 3600 270 / /
viscum 230 / / 570 22.13
viscumTT 230 3600 270 570 22.13
CDs 230 / / / /
Represented is the composition of each mistletoe extract, used in the
experiments. TT contain mostly oleanolic acid (OA) and betulinic acid (BA)
without mistletoe lectin (ML) or viscotoxins (VT). Viscum contains β-
cyclodextrins (CDs), ML and VT and does not include OA or BA. ViscumTT is a
combination of both single extracts. The concentrations of ML-I as well as OA
and BA in each stock solution are shown. The concentrations of ML (for
viscum) and OA (for TT) function as marker substances
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carbocyanine iodide (JC-1) and propidium iodide (PI) were
purchased from Sigma Aldrich (Munich, Germany). Tween,
acrylamide and dithiotreitol (DTT) were purchased from
Carl Roth GmbH (Karlsruhe, Germany) and 4-
hydroperoxyifosfamide (active metabolite of ifosfamide,
4OOH) was obtained from Niomech (Bielefeld, Germany).
Doxo was kindly provided by the hospital pharmacy of the
Charité.
Cell culture
The human osteosarcoma cell lines 143B and Saos-2
were obtained from American Type Culture Collection
(ATCC, Manassas, USA). 143B cells were cultured in
RPMI 1640, Saos-2 in McCoy’s 5A, both supplemented
with 10% heat inactivated FCS 100 U/mL penicillin and
100 μg/mL streptomycin. For the experiments, 143B
cells were seeded in 4*105 onto 6 well and 2*105 onto 12
well plates. For Saos-2 cells 1*106 onto 6 well and 5*105
onto 12-well plates were seeded. Cells cultured 24 h to
allow cell attachment and treated with viscum (2.5, 5,
10 ng/mL), TT (40, 50, 60 μg/mL) and viscumTT (2.5 +
40, 5 + 50, 10 + 60 ng/mL + μg/mL) 24 and 48 h.
Proliferation assay WST-1
Cell proliferation reagent WST-1 (Roche, Grenzach-
Whylen, Germany) was used for quantification of cell
proliferation. 2*104 143B cells and 5*104 Saos-2 cells
were seeded onto 96-well plates in triplicates and incu-
bated 24 and 48 h with viscum, TT and viscumTT in ris-
ing concentrations (see Cell culture). 10 μl WST-1
reagent were added and the absorbance of the dye solu-
tion was measured after 2 h of incubation in a humidi-
fied atmosphere by an ELISA reader (Thermo Fisher
Scientific, Bonn, Germany).
Proliferation measurement and exclusion of early
cytotoxicity
Cell number was calculated using a CASY® Cell Counter
from Schaerfe System GmbH (Reutlingen, Germany).
Alterations of proliferation were expressed in percent in
relation to control cells (100% vitality). Lactate dehydro-
genase (LDH) release was measured photometrically at
490 nm after 2 h using the Cytotoxicity Detection Kit
(Roche, Grenzach-Wyhlen, Germany) to preclude an
early cytotoxic effect.
Detection of apoptosis
Both osteosarcoma cell lines were seeded onto 6 well
plates and incubated with increasing concentrations of
viscum, TT and viscumTT in rising concentrations (see
Cell culture) for 24 and 48 h. For the co-treatment in-
vestigations, cells were seeded onto 12 well plates,
treated with lower concentrations of viscum (1.5, 2,
2.5 ng/mL), TT (20, 30, 40 μg/mL) and viscumTT
(combination in rising concentrations). Additional,
VP16 (0.5 μg/mL), Doxo (0.1 μg/mL for 143B cells,
0.05 μg/ml for Saos-2 cells) and 4OOH (0.05 μg/mL)
were added and incubated for 48 h. Then cells were
washed twice with PBS, re-suspended in 100 μl binding
buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl,
5 mM CaCl2) and stained with APC-conjugated
Annexin V (BD Bioscience, Heidelberg, Germany) and
1 mg/mL PI according to manufacturer’s instructions
to measure apoptosis. The cells were analyzed by flow
cytometry (FACSCalibur, Becton Dickinson, Heidelberg,
Germany). The results were evaluated with FlowJo Soft-
ware (TreeStar, Ashland, USA).
Measurement of mitochondrial membrane potential
(ΔΨm)
The ΔΨm was measured using JC-1. After incubation,
the cells were washed, re-suspended in 750 μl PBS and
incubated with 2.5 μg/mL JC-1 for 30 min at 37 °C, 5%
CO2. After a further PBS washing step the cells were
analyzed by flow cytometry. As reference, control cells
were treated with 50 μM depolarizing carbonyl cyanide
3-chlorophenylhydrazone (CCCP) (Sigma Aldrich,
Munich, Germany) for 30 min.
Measurement of caspase activity
After an incubation time of 24 h with viscum, TT and
viscumTT in rising concentrations (see Cell culture),
CASP3, CASP8 and CASP9 activity was assessed using
Promokine’s Green Caspase Staining Kit (Promokine,
Heidelberg, Germany). For this, cells were incubated
with the nontoxic, irreversibly capase-binding cell-
permeable FITC-LEHD-FMK, FITC-IETD-FMK and
FITC-DEVD-FMK according to manufacturer’s instruc-
tions. Then the cells were analyzed by flow cytometry.
For caspase inhibitor assay, 143B and Saos-2 cells were
pre-incubated with 100 μM pan-caspase inhibitor Z-
VAD-FMK for 1 hour and subsequently treated with ≈
IC 50 of TT and viscumTT and ≈ IC 25 of viscum for
24 h. As solvent control DMSO was added. Apoptosis
induction was investigated by Annexin V/PI staining and
flow cytometry as described earlier.
Western Blot
For protein extraction 143B cells were incubated with
increasing concentrations of viscum, TT and viscumTT
for 24 h. The cells were washed twice and lysed using
RIPA buffer (Carl Roth GmbH, Karlsruhe, Germany) in-
cluding proteinase inhibitor for 30 min. Next, the cells
were centrifuged at 14,000 rpm for 30 min at 4 °C. Pro-
tein concentration was determined by Bradford reagent.
After transfer of proteins to nitrocellulose membrane
(Bio-Rad, Munich, Germany) primary antibody was in-
cubated over night at 4 °C. The following primary
Kleinsimon et al. BMC Complementary and Alternative Medicine  (2017) 17:26 Page 3 of 13
antibodies were used: CASP3 (#9662, Cell Signaling
Technology, Danvers, MN, USA), PARP1 (#9542, Cell
Signaling Technology), CLSPN (#2800, Cell Signaling
Technology), BIRC5 (#2803, Cell Signaling Technology),
TP53 (sc-73566, Santa Cruz Biotechnology, CA, USA),
XIAP (#610716, BD Biosciences), BCL2 (#2870, Cell Sig-
naling Technology), BID (#2002, Cell Signaling Technol-
ogy), cytochrome c (#4280, Cell Signaling Technology),
ß-actin (#A3854, Sigma-Aldrich) and GAPDH (sc25778,
Santa Cruz Biotechnology, CA, USA). Protein signal was
detected by HRP-conjugated secondary antibodies (Bio-
Rad, Munich, Germany) and visualized by ECL (Thermo
Fisher Scientific, Bonn, Germany) and ChemiDoc. For
mitochondrial protein preparation, cells were lysed as
described above and the cytosolic fraction was isolated
as published earlier [18]. Then, the cytosolic fraction
was seperated by SDS-PAGE, transferred to nitrocellu-
lose membrane and incubated with monoclonal cyto-
chrome c antibody. Actin was used as loading control.
ex vivo cultured osteosarcoma primary cells
After routine surgical resection, a tumor sample from
the tibia was obtained as treatment ‘residue’ from a 12-
year-old boy with first-diagnosis osteosarcoma without
lung metastases. This tumor material was not explicitly
collected for this research. Histopathology confirmed the
diagnosis. Immediately after surgical excision, the tissue
was dissected into smaller pieces and cultured as a pri-
mary explant in RPMI 1640 base medium with L-
glutamine supplemented with 20% heat-inactivated FCS
and 1% penicillin/streptomycin solution. When cells dis-
sociated from the explant to form a confluent monolayer
culture ex vivo cells were treated in 4 trypsinized pas-
sages. For investigations, cells were seeded onto 12-well
microtiter plates at 2.5×105/well for treatment with vis-
cum, TT or viscumTT extracts. For each tested dose,
single well plate was used and experiment was per-
formed at least in three sets of independent experiments.
Then, proliferation, apoptosis induction, activation of
CASP8, CASP9, CASP3 and loss of ΔΨm were exam-
ined. Written informed consent was obtained from the
patient in accordance with the Declaration of Helsinki,
and the study was approved by the local ethics commit-
tee of the Charité- Universitätsmedizin Berlin.
Statistics
All in vitro experiments were performed at least in three
sets of independent experiments, for which means ±
standard error were calculated and plotted in bar graphs.
Webb’s fractional product (*Fp) >1 was calculated for
the synergistic effect of viscumTT and the chemothera-
peutic agents on apoptotic induction in vitro as de-
scribed earlier [18, 30]. Briefly, Webb’s fractional
product based on the formula: E1;2exp = (E1 + E2-E1*E2),
with E1;2exp = expected (calculated) effect of the combin-
ation viscumTT. E1 = observed effect of TT; E2 = ob-
served effect of viscum; E1;2obs = observed effect of
combined mixture viscumTT. Fp = E1;2obs/E1;2exp. Values
Fp > 1 represent synergistic, whereas Fp = 1 additive and
Fp < 1 antagonistic effects. One-way ANOVA was used
for calculation of significance. All results with p ≤ 0.05
were considered significant.
Results
Viscum, TT and viscumTT did not induce early
cytotoxicity but inhibit cell proliferation in vitro
Early cytotoxicity was analyzed by Cytotoxicity Detec-
tion Kit after 2 h whereby LDH release was investigated.
Neither 143B nor Saos-2 cells showed any considerable
increase of LDH in the supernatant (Fig. 1a). Therefore,
an unwanted early cytotoxicity via necrosis could be
excluded.
For assessment of inhibition of proliferation, cells were
counted using a CASY® Cell Counter and proliferation
was estimated from total numbers of cells compared to
control cells. Inhibition of proliferation was confirmed
by WST-1 assay. Both cell lines showed strong inhibition
of cell proliferation in a dose-dependent manner after
treatment with viscum, TT and viscumTT after 24 h and
48 h (Fig. 1b and c). TT inhibited cell proliferation less
than viscum. For viscumTT the effect was enhanced in
both cell lines. With the WST-1 assay a synergistic effect
could be determined.
ViscumTT induces apoptosis in both cell lines
synergistically
Next, the potential of viscum, TT and viscumTT for
apoptosis induction was determined. 143B and Saos-2
cells were analyzed by annexin V-APC/PI staining and
flow cytometry after 24 and 48 h treatment. Interest-
ingly, viscum led to only a slight apoptosis induction in
both cell lines, whereas TT and viscumTT triggered
apoptosis in a dose- and time-dependent manner after
24 h (Fig. 2a). This effect was enhanced after 48 h
(Fig. 2a) for all three extracts. ViscumTT led even to a
synergistic apoptosis induction in both osteosarcoma cell
lines (Fig. 2a). The apoptosis induction was confirmed
by cleavage of PARP and proteolytic processing of
CASP3 after western blot analysis (Fig. 2b).
Viscum, TT and viscumTT induce mitochondrial
depolarization and cytochrome c release
For investigation whether mitochondria are involved in
the apoptotic process, the Δψm depolarization was eval-
uated by JC-1 and FACS analyses after 24 h extract
treatment. ViscumTT treatment led to a significant
dose-dependent loss of Δψm (Fig. 2c) and confirmed the
synergistic effect observed in annexin V staining. In
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Fig. 1 Viscum, TT and viscumTT inhibit proliferation without early cytotoxicity in 143B and Saos-2 cells. Early cytotoxicity was analyzed via LDH
release into the culture medium (a). Proliferation was examined by CASY® Cell Counter (b) and WST-1 assay (c). All results are presented as
percentage of untreated control (Ctrl). Control cells were set to 100%. Means ± SD are shown. Mistletoe lectin (ML) and oleanolic acid (OA)
concentrations were used as a measure of viscum and TT active agent extract concentration. (p≤ 0.05, n ≥ 3, *Fp > 1 = synergism)
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Fig. 2 (See legend on next page.)
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(See figure on previous page.)
Fig. 2 ViscumTT induces apoptosis synergistically and leads to loss of mitochondrial membrane potential (ΔΨm). The means ± SD of apoptotic
cells are shown (a). Mistletoe lectin (ML) and oleanolic acid (OA) concentrations were used as a measure of viscum and TT. (p≤ 0.05, n≥ 3,
*Fp > 1 = synergism). Apoptosis was confirmed by proteolytic processing of CASP3 and cleavage of PARP (b). β-actin was used as loading
control. The means ± SD of loss of mitochondrial membrane potential (ΔΨm) (c) and carbonyl cyanide 3-chlorophenylhydrazone (CCCP was
used as positive control (p ≤ 0.05, n ≥ 3, *Fp > 1 = synergism) are shown. Cytochrome c (d) release confirmed mitochondrial pathway activation.
β-actin served as loading control
Fig. 3 ViscumTT enhances activation of CASP8 and CASP9. FITC-LEHD-FMK and FITC-IETD-FMK staining and FACS analyses represented activity of
CASP8 and CASP9 (a). Pre-incubation with ZVAD-FMK pan-caspase inhibitor confirmed caspase-dependent apoptosis induction (b) (mean ± SD,
p≤ 0.05, n≥ 3, *Fp > 1 = synergism)
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143B cells the observed effect was much less for all three
extracts in comparison to Saos-2 cells.
Δψm depolarization and resulting cytochrome c re-
lease into the cytosol mediate apoptosis induction via
the intrinsic pathway. Based on western blot analyses
cytochrome c was detected in the cytosol fraction after
treatment with viscum and viscumTT (Fig. 2c) in 143B
and additionally after TT in Saos-2. These results sug-
gest the hypothesis that viscum, TT and viscumTT in-
duce apoptosis via the mitochondrial pathway.
Viscum TT leads to activation of CASP8 and CASP9
To get a closer look at the apoptosis mechanism, we
assessed the activation of CASP8 and CASP9. These
caspases are upstream initiator protease caspases,
which will be activated by the extrinsic (CASP8) and
intrinsic (CASP9) apoptotic pathways and initiates
cleavage of effector caspase CASP3. CASP3 and the
presence of cytochrome c can additionally induce cleav-
age of CASP8 as a feedback mechanism without recep-
tor mediation [31]. CASP8 was affected by viscum and
TT alone in both cell lines (Fig. 3a). CASP9 (Fig. 3a)
was activated after the treatment with TT and vis-
cumTT but viscum alone had practically no effect,
while viscumTT treatment led to clearly synergistic ac-
tivation of both caspases. After pre-incubation for 1 h
with ZVAD-FMK pan-caspase inhibitor apoptosis in-
duction was significantly reduced up to 40% in both cell
lines treated with viscumTT and up to 10 to 15% in
both cell lines treated with viscum and TT (Fig. 3b).
These results validated the essential role of caspases in
apoptosis induction by viscumTT.
ViscumTT alters apoptosis associated proteins
Because of previous knowledge, we wanted to know
which proteins of the bcl-2 family and inhibitor of apop-
tosis proteins (IAPs) are altered in osteosarcoma. All
three extracts led to down-regulation of anti-apoptotic
protein BCL2 with simultaneous up-regulation of pro-
apoptotic protein BAX in 143B cells (Fig. 4c). A reduced
expression of XIAP and BIRC5 was observed in both cell
lines (Fig. 4a and b). Interestingly, the expression of
CLSPN was strongly down-regulated by viscum, TT and
viscumTT in 143B cells, whereas in SaOS-2 control cells
CLSPN is not expressed at all. Additionally, decreased
BID expression with cleavage of BID into tBID after TT
treatment was also observed (Fig. 4a and b). p53 was
down-regulated by viscum, TT and viscumTT in 143B.
Synergistic effect of viscumTT is confirmed in patient-
derived osteosarcoma cells
To investigate whether there is any apoptotic effect on pri-
mary tumor material, derived osteosarcoma cells were
treated with viscum, TT and viscumTT. Figure 5 shows in-
hibition of cell proliferation (A) with further induction of
apoptosis (B) and loss of Δψm (C). Additionally, activation
of CASP3, −8 and −9 (D) was synergistically activated
after viscumTT treatment. These results confirmed our in
vitro data.
Co-treatment with chemotherapeutic drugs increases
apoptotic response
Because of the increasing presence of resistances to con-
ventional chemotherapy in osteosarcoma a combination
treatment with complementary therapy approaches is
becoming more and more important. Beside treatment
Fig. 4 Viscum, TT and viscumTT alter apoptosis associated protein expression levels. Western blots of p53, BCL-2, BAX and BID as well as XIAP, CLSPN
and BIRC5 after viscum, TT and viscumTT treatment in 143B (a, c) and SaOs-2 (b) cells. GAPDH and β-actin served as loading controls (n≥ 3)
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with viscum, TT and viscumTT, osteosarcoma cell lines
were co-treated with Doxo, VP-16 and 4OOH to exam-
ine apoptosis induction. In both cell lines apoptosis was
induced even when TT and viscum alone were added to
chemotherapeutic drugs. This effect was additionally en-
hanced in 143B after co-treatment with viscumTT
(Fig. 6a). In Saos-2 cells (Fig. 6b) the enhancer effect of
viscumTT is rather low. The strongest synergistic effect
was observed when VP16 or Doxo was combined with
viscumTT in a lower dose. Higher dosage led to an addi-
tive effect (Table 2).
Discussion
In this study we investigated the apoptotic potential of
the whole mistletoe extract viscumTT in comparison to
its constituents viscum and TT. ViscumTT very effect-
ively inhibited cell proliferation and synergistically in-
duced apoptosis in osteosarcoma cells in vitro in a
time- and dose-dependent manner. Our in vitro data
correlate with the assumption that whole plant extracts
are often more potent in anti-cancer activity than the
single ingredients [32, 33]. The mechanisms of action
of the individual constituents are still unclear. We and
others were able to demonstrate a caspase-dependent
apoptosis induction with involvement of CASP8,
CASP9 and CASP3 [19, 34]. Bantel et al. proved the ac-
tivation of CASP8 without any death receptor signalling
[17], which supported the assumption that apoptosis is
mainly mediated by the mitochondrial pathway. CASP3
[35] and cytochrome c [31] can also activate CASP8 in
Fig. 5 ViscumTT synergistically induces apoptosis in primary material from an osteosarcoma patient. Inhibition of proliferation (a), apoptosis
induction (b), loss of mitochondrial membrane potential (ΔΨm) (c) and CASP8, CASP9 and CASP3 (c) activity are shown as mean % ± SD.
Proliferation was measured by CASY® cell counter and control was set to 100%. Alterations of proliferation were expressed in % of control
cells (p≤ 0.05, n ≥ 3, *Fp > 1 = synergism)
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a feedback mechanism. Further cleavage of BID by
CASP8 triggers a stronger apoptotic response by an in-
trinsic mechanism. We observed activation of CASP3,
CASP8 and CASP9 with additional loss of mitochon-
drial membrane potential, BID cleavage and cyto-
chrome c release after viscumTT treatment. TT
treatment led to no cytochrome c release in Saos-2 al-
though CASP9 was activated (Figs. 2 and 3). Both cell
lines are almost resistant to viscum after 24 h and in
143B cells CASP9 was interestingly not affected. Older
studies of our group observed CASP9 and CASP8 acti-
vation after viscum treatment in different leukaemia
cell lines [18, 19]. However, after addition of TT CASP9
was strongly activated in both cell lines. These results
support the statement that the anti-cancer effect is
often dependent on cell line and tumor entity. In
addition, different OA derivatives induce apoptosis dir-
ectly mediated by CASP8 in various cancer cells [23,
36, 37]. Apoptosis induction by VAE alters apoptosis
associated protein levels of the BCL2 family proteins
BAX and BCL2 [38, 39]. This is in line with our results.
p53 interacts directly with BCL-2 family members [40]
and regulates the expression of BAX and BCL2 in
apoptosis [41, 42]. p53 was down-regulated by all three
extracts in 143B. In hepatocarcinoma cells [38] and hu-
man lymphocytes [39] down-regulation of p53 was also
observed. Saos-2 cells are null mutants for p53 but
apoptosis was also induced after treatment. These
Fig. 6 ViscumTT co-treatment with doxorubicin (Doxo), etoposide (VP16) and ifosfamide (4OOH) enhances apoptosis induction synergistically.
FACS analyses of apoptotic cells in % ± SD of 143B (a) and SaOS-2 (b) cells. Mistletoe lectins (MLs) and oleanolic acid (OA) were used as marker
substances for viscum and TT (p≤ 0.05, n ≥ 3, *Fp > 1 = synergism)
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results suggest the assumption that apoptosis induction
is p53 independent in these osteosarcoma. Cell lines.
Furthermore, VAEs led to reduction in several IAP fam-
ily members such as XIAP and BIRC5 in Ewing sar-
coma (Twardziok et al. accepted)), AML [19], colon
cancer and epidermoidal cancer [43]. This is in line
with our present results. The abilities of IAPs to inhibit
caspases, assemble pro-apoptotic protein complexes
and mediate expression of anti-apoptotic proteins,
make them promising targets in cancer treatment [44].
Interestingly, CASP3 is able to degrade its own inhibi-
tor (XIAP) which again enhances CASP3 activity and
consequently induces apoptosis [45]. In addition, XIAP
and BIRC5 are also affected by derivatives of OA [46,
47] and BA [48]. It is evident from our results that vis-
cumTT combines the anti-cancer effects cell type inde-
pendently, but seems to modulate the mechanism of
apoptosis derived from triterpene acids and mistletoe
lectins. The mechanism of the synergistic action of vis-
cumTT could not yet be decoded. Recently, it was
shown that after a short incubation time uptake of ML
by 143B cells after viscum treatment only occurred
after addition of TT [49]. Our data suggest that ML up-
take needs more time in 143B cells because after 24 h
an anti-proliferative effect was observed. However, this
observation leads to the hypothesis that triterpenic
acids improve the uptake of viscum, which could also
be one explanation for the synergistic effect. Triterpe-
nic acids are able to embed in cell membranes, which
leads to their disturbance [50, 51], and interact with an-
ionic phospholipids [52]. Further investigations of this
are necessary. In the future, reduction of side effects
and overcoming of resistances during chemotherapy
will be of increasing interest. Some studies were even
able to show an enhancement of cytotoxicity when
chemotherapy was combined with VAE in vitro [28].
An optimal anti-tumor effect was demonstrated in
K562 leukaemia cells after co-treatment with VAE and
sub-apoptotic doxorubicin concentrations [27]. Also,
VP16 led to an enhanced apoptosis induction after
combined incubation with ML-I [17]. In our study we
observed an additional synergism when viscum, TT and
viscumTT were co-treated with Doxo, 4OOH and
VP16 in 143B cells. In Saos-2 cells the enhanced apop-
totic effect was additive rather than synergistic. The
synergistic apoptosis induction after co-treatment with
viscum, TT and viscumTT and 4OOH was demon-
strated here for the first time. Generally, hight potential
of apoptosis induction, also in combination with clas-
sical chemotherapeutic drugs, promises importance as
additional therapy in osteosarcoma.
Conclusion
In this study we demonstrated the high potential of
viscumTT with regard to apoptosis induction in osteo-
sarcoma. It induced apoptosis synergistically. This ef-
fect is further enhanced when it is co-administered
with Doxo, VP16 and 4OOH. Because of increasing
problems during chemotherapy such as resistances or
negative side effects, new therapeutic approaches will
become more important in the future. Hence, vis-
cumTT may represent a promising adjuvant therapy
in pediatric osteosarcoma.
Table 2 Webb’s fractional product of co-treatment of chemotherapy with viscum, TT and viscumTT
TT viscum viscumTT
A
DOXO 0.1 + 20 0.1 + 30 0.1 + 40 0.1 + 1.5 0.1 + 2 0.1 + 2.5 0.1 + 1.5 + 20 0.1 + 2 + 30 0.1 + 2.5 + 40
*FP 1.39 1.37 1.32 1.22 1.07 1.11 1.06 1.32 1.26
VP16 0.5 + 20 0.5 + 30 0.5 + 40 0.5 + 1.5 0.5 + 2 0.5 + 2.5 0.5 + 1.5 + 20 0.5 + 2 + 30 0.5 + 2.5 + 40
*FP 3.20 2.48 1.73 2.44 1.86 1.72 2.00 1.79 1.27
4OOH 0.5 + 20 0.5 + 30 0.5 + 40 0.5 + 1.5 0.5 + 2 0.5 + 2.5 0.5 + 1.5 + 20 0.5 + 2 + 30 0.5 + 2.5 + 40
*FP 1.14 1.10 1.28 1.37 1.20 0.97 1.19 1.13 1.20
B
DOXO 0.05 + 20 0.05 + 30 0.05 + 40 0.05 + 1.5 0.05 + 2 0.05 + 2.5 0.05 + 1.5 + 20 0.05 + 2 + 30 0.05 + 2.5 + 40
*FP 0.83 0.82 0.82 0.72 0.84 0.85 0.80 0.89 0.83
VP16 0.5 + 20 0.5 + 30 0.5 + 40 0.5 + 1.5 0.5 + 2 0.5 + 2.5 0.5 + 1.5 + 20 0.5 + 2 + 30 0.5 + 2.5 + 40
*FP 0.99 1.00 0.94 0.85 0.89 1.01 0.85 0.84 0.93
4OOH 0.5 + 20 0.5 + 30 0.5 + 40 0.5 + 1.5 0.5 + 2 0.5 + 2.5 0.5 + 1.5 + 20 0.5 + 2 + 30 0.5 + 2.5 + 40
*FP 1.22 1.23 1.04 0.75 0.85 0,86 0.85 0.92 0.91
Co-treatment of viscum (ng/mL), TT (μg/mL) and viscumTT with doxorubicin (Doxo (0.1 (A), 0.05 (B) μg/mL)), etoposide (VP16 (0.5 μg/mL)) and ifosfamide (4OOH
(0.5 μg/mL)) led to synergistic or additive apoptosis induction in 143B (A) and Saos-2 (B) cells (*Fp > 1 = synergistic effect, *Fp = 1 = additive effect). Oleanolic acid
(OA) and mistletoe lectin (ML) were used as marker substances for viscum and TT
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